Introduction
============

COPD is a major public health problem. It is the fourth leading cause of morbidity and mortality worldwide and is associated with increasing economic costs and social burdens.[@b1-copd-12-509] COPD is characterized by progressive airflow limitation that is not fully reversible.[@b1-copd-12-509] Forced expiratory volume in 1 second (FEV~1~) and the rate of annual decline in FEV~1~ are the most widely used outcome measures for clinical trials of pharmacotherapy or other interventions, such as smoking cessation, for COPD.[@b2-copd-12-509] Frequency of exacerbation[@b3-copd-12-509] has been shown to be one of the factors affecting annual decline in FEV~1~. The forced oscillation technique (FOT) is a noninvasive method used to measure lung mechanics.[@b4-copd-12-509] Recently, its usefulness in the evaluation or management of obstructive lung diseases, including COPD and asthma, has been reported.[@b5-copd-12-509]--[@b8-copd-12-509] Although FOT is suitable for repeated measurements because of the noninvasive nature, to our knowledge, no data are available concerning long-term changes in respiratory system impedance in patients with COPD. Additionally, although exacerbations are important events in patients with COPD because they contribute to a further decline in lung function,[@b3-copd-12-509] impaired health-related quality of life,[@b9-copd-12-509],[@b10-copd-12-509] socioeconomic burden,[@b11-copd-12-509] and poor prognosis,[@b12-copd-12-509] there are no data on the impact of exacerbations on FOT parameters in patients with COPD. Therefore, we carried out a study of longitudinal changes in respiratory system impedance and the influence of exacerbations thereon.

Methods
=======

The study design is a prospective observational study. Between March 2011 and March 2012, 83 outpatients with a diagnosis of COPD, who attended Kobe City Medical Center West Hospital (a 358-bed community teaching hospital in Kobe, Japan), were assessed for eligibility. All patients fulfilled the inclusion criteria of: 1) a smoking history of more than 20 pack-years; 2) a maximal FEV~1~/forced vital capacity ratio \<0.7; 3) regular management and treatment at our outpatient clinic over 3 months; 4) no exacerbations in the previous 6 weeks; 5) no other lung diseases; 6) no uncontrolled comorbidities such as severe cardiovascular disease or malignancy; and 7) sufficient cognitive function to complete the questionnaire. The staging of COPD was assessed in accordance with the 2014 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.[@b1-copd-12-509] We defined an exacerbation as a symptomatic deterioration requiring treatment with antibiotics or systemic corticosteroids. Periodic assessment was postponed when patients were prescribed courses of prednisolone or treatment with antibiotics for exacerbations of COPD in the month prior to the visit.

The study was approved by the Institutional Review Board of Kobe City Medical Center West Hospital (reference number 14-023), and informed consent was obtained from all patients before entry into the study.

Data on patient characteristics (age, sex, body mass index, smoking history, current smoking status, and COPD stage), lung function (post-bronchodilator FEV~1~), blood tests (neutrophils and eosinophils), FOT (MostGraph^®^; CHEST MI, Tokyo, Japan), and COPD assessment test results[@b13-copd-12-509] were collected at enrollment. Lung function and FOT were examined every 6 months until March 2016. The same equipment and standardized methods were used in the examination at enrollment and the last follow-up.

Measurements
------------

### Lung function tests

After the patients had inhaled bronchodilator (salbutamol 400 µg) spirometry, subdivisions of lung volume were measured using a Chestac-65V (Chest M.I.). The predicted pulmonary function test values were calculated based on the Japanese Respiratory Society guidelines.[@b14-copd-12-509] In this paper, FEV~1~ means post-bronchodilator FEV~1~.

### Forced oscillation system

After the use of the inhaled bronchodilator (salbutamol 400 µg), respiratory impedance was measured using the commercially available FOT device (MostGraph^®^). During the measurements, the subjects were placed in the seated position, wore a nose clip, and breathed at tidal volume through a mouthpiece. In addition, their cheeks were supported to reduce upper airway shunting. A noise signal was applied to the airway, and the respiratory system impedance was automatically calculated using the MostGraph-01 software (version 1.31, Chest M.I.). Recordings were performed for 60 seconds after steady breathing was confirmed. The mean respiratory system resistance (Rrs) at 5 Hz (R5), mean Rrs at 20 Hz (R20), their difference (R5--R20), respiratory system reactance (Xrs) at 5 Hz (X5), and resonant frequency (Fres) were calculated after manually excluding artifacts (whole-breath analysis). Differences between mean Rrs, Xrs, and Fres in the expiratory phase and inspiratory phase were also examined (expressed as ⊿). Whole-breath analysis and within-breath analysis were performed automatically by the software. The average levels of at least 3 acceptable measurements were used.

### Measurement of FeNO

Fractional exhaled nitric oxide (FeNO) levels were measured using a nitric oxide monitor (NIOX MINO^®^, Aerocrine, Solna, Sweden) according to the 2005 American Thoracic Society/European Respiratory Society guidelines.[@b15-copd-12-509] The subjects were asked about current medications or food intake that could interfere with the FeNO measurement results, and were instructed to avoid smoking, exercise, and ingestion of food, water, or caffeine for at least 1 hour before testing.

While seated, the subjects exhaled fully, inhaled for 2--3 seconds to total lung capacity through an NIOX filter, and then exhaled with an upper airway pressure of 5--20 cm H~2~O. FeNO measurements were taken from a 3-second stable plateau of the exhaled NO concentration. The lowest detection limit of the NIOX MINO^®^ is 5 parts per billion (ppb), and values \<5 ppb were regarded as 2.5 ppb. The average values of at least 2 acceptable measurements were used.

Statistical analysis
--------------------

All statistical analyses were performed using JMP 9 software (SAS Institute, Cary, NC, USA). Categorical data were summarized as counts, and quantitative data were summarized as the median. We divided the patients into two groups, ie, patients with exacerbations during the observation period and those without. The frequency of exacerbations was obtained by dividing the times of exacerbations during the observation period by the years of observation. The annual changes were obtained from the slope of the linear regression curve. Baseline variables and annual changes between the groups were compared using the chi-squared test for categorical variables and unpaired *t*-tests or Mann-Whitney *U* tests as appropriate for continuous variables.

Results
=======

Patient characteristics
-----------------------

The characteristics of the study subjects as well as the baseline respiratory system impedance and FEV~1~ are shown in [Tables 1](#t1-copd-12-509){ref-type="table"} and [2](#t2-copd-12-509){ref-type="table"}. Fifty-eight patients with COPD were enrolled in this study and the final study population comprised 51 patients. Seven patients were excluded for the following reasons: death (1 patient), serious condition (1 patient), new lesions of the lung (3 patients), and loss of follow-up (2 patients). The median duration of follow-up was 57 months. All the subjects were in a stable condition and had not had exacerbations for 3 months prior to their examination. The median CAT score was 6, indicating that COPD in the study population was controlled.

Medication
----------

Four patients (8%) were not taking any medication for COPD, and the remaining patients (47 patients) were using a long-acting muscarinic antagonist; 19 patients were using a combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA). There was a tendency for patients with severe COPD to be prescribed a combination of ICS and LABA.

Annual changes in respiratory system impedance and FEV1
-------------------------------------------------------

The annual changes in respiratory system impedance and FEV~1~ are shown in [Table 3](#t3-copd-12-509){ref-type="table"}. FEV~1~ decreased and almost all of the absolute values for respiratory system impedance increased.

### The impact of exacerbations

#### Patient characteristics

The characteristics of the study subjects and the baseline respiratory system impedance and FEV~1~ subdivided by episodes of exacerbation are shown in [Tables 4](#t4-copd-12-509){ref-type="table"} and [5](#t5-copd-12-509){ref-type="table"}. Twenty-five subjects experienced exacerbations, and the median rate of exacerbations in this group was 0.44 times per year. The median times of exacerbations experienced in the year before recruitment were significantly higher in the group with exacerbation. There was no significant difference in FOT parameters or lung function tests.

Annual changes in respiratory system impedance and FEV~1~
---------------------------------------------------------

The annual changes in measurements in the subjects subdivided by episodes of exacerbation are shown in [Table 6](#t6-copd-12-509){ref-type="table"}. The changes in FEV~1~, R5, X5, and Fres were significantly larger in the group with exacerbations. Annual changes in the difference between the mean X5 in the expiratory phase and that in the inspiratory phase were significantly larger in the group with exacerbations. There was no significant difference in annual changes for parameters other than FEV~1~ and FOT between the groups.

Discussion
==========

This prospective observational study demonstrated that the absolute values for annual changes in respiratory system impedance measured by FOT increase and that the annual changes in respiratory system impedance were significantly greater in patients with exacerbations than those in without. To our knowledge, this is the first longitudinal study to demonstrate the annual changes in respiratory system impedance and its relationship in patients with COPD.

In our study, the annual decline in FEV~1~ was significantly larger in the exacerbation group. The GOLD guidelines emphasize that COPD exacerbations accelerate the rate of decline in lung function.[@b1-copd-12-509] Kanner et al reported that lower respiratory tract illness promoted a decline in FEV~1~ in current smokers with mild COPD, but not in ex-smokers.[@b16-copd-12-509] Furthermore, they showed a faster annual decline in FEV~1~ in patients with frequent exacerbations defined by symptom-based criteria (more than 2.92 events per person per year) when compared with patients suffering infrequent exacerbations (less than 2.92 events per person per year).[@b3-copd-12-509] In the present study, 60% of the subjects were current smokers. Furthermore, the criteria for exacerbation in our study were more stringent than in the study reported by Donaldson et al, because exacerbations in our study required not only a symptomatic deterioration but also treatment with antibiotics and/or systemic corticosteroids.[@b3-copd-12-509] Thus, it is reasonable that the effect of exacerbation events on the annual decline in FEV~1~ in our study was significantly large.

In this study, not only a significant annual decline in FEV~1~ but also a significant annual increase in respiratory system impedance was observed. Moreover, it is evident that the annual changes in R5, X5, and Fres were significantly greater in subjects with exacerbation than in those without. There have been cross-sectional studies about the association between lung function tests and FOT parameters that have shown that the strongest correlation is generally found between Fres and Xrs and FEV~1~ in both asthma and COPD.[@b8-copd-12-509],[@b17-copd-12-509] To date, however, it is not clear why Fres or X5 has such significant relationships with markers of airway obstruction. In this study, the ratio of annual decline of FEV~1~ to the baseline value was 1.8%, while the ratio of the changes in respiratory system impedance to baseline value was 1.6% for R5, 2.3% for R20, 1.1% for R5--R20, 7.6% for X5, and 5.9% for Fres ([Figure 1](#f1-copd-12-509){ref-type="fig"}). The ratio of annual changes in respiratory system impedance, especially in X5 and Fres, was more apparent than that of FEV~1~. Moreover, in the group of subjects with and without exacerbations, the ratios of annual changes to the baseline value were 3.0% and 0.8% for FEV~1~, 5.7% and −1.0% for R5, 1.5% and −2.6% for R20, 4.4% and −8.1% for R5--R20, 19.1% and 1.4% for X5, and 8.7% and 2.1% for Fres, respectively ([Figure 2](#f2-copd-12-509){ref-type="fig"}). The ratio of X5 and Fres was remarkably greater in subjects with exacerbations than in those without. Therefore, X5 and Fres could reflect the time course of changes in the airway and the influence of exacerbations on the airway more clearly than FEV~1~. Johnson et al reported on the recovery of respiratory system impedance from a single episode of COPD exacerbation.[@b18-copd-12-509] Comparing respiratory system impedance within 48 hours from an episode of exacerbation with that 6 weeks after the first assessment, although there were no changes in Rrs, Xrs recovered by 27.4% at inspiration and 37.1% at expiration.[@b18-copd-12-509] This recovery of Xrs was correlated with an improvement in arterial partial pressure of oxygen, symptoms, and health-related quality of life.[@b18-copd-12-509] In their study, baseline respiratory system impedance before the episode of exacerbation was not evaluated, so the irreversible influence of exacerbation on respiratory system impedance was unknown. However, our study suggests an influence of exacerbation on respiratory system impedance, especially on Xrs. Studies demonstrating the impact of a single episode of exacerbation on respiratory system impedance will be needed.

Although the relationship between lung function tests and FOT has often been mentioned, the information provided by lung function tests is obtained by forced respiration, whereas the information provided by FOT is obtained by resting respiration, so FOT and lung function tests are not of the same modality. FOT can be useful for long-term assessment of COPD as a representative chronic lung disease.

In our study, annual changes in the difference between the expiratory phase and the inspiratory phase of only whole-breath X5 were significantly larger in the group with exacerbation. Dellacà et al reported that within-breath variations in Xrs (⊿X5) measured by FOT allowed detection of expiratory flow limitation (EFL).[@b19-copd-12-509]--[@b21-copd-12-509] This phenomenon is common in patients with severe COPD and a major determinant of dynamic hyperinflation and exercise limitation. EFL is caused by a loss of lung elastic recoil. It is supposed that reactance normally reflects the elastic and inertial properties of the respiratory system but, with flow limitation, oscillatory signals cannot pass through the choke points and reach the alveoli, producing a marked reduction in apparent compliance and a fall in reactance.[@b19-copd-12-509]--[@b21-copd-12-509] Dynamic airway narrowing during quiet breathing at rest has been visually detected in a patient with severe COPD by high-speed electron-beam computed tomography.[@b22-copd-12-509] Our results indicate that exacerbations in COPD subjects might result in deterioration of EFL, suggesting the utility of ⊿X5 as a surrogate marker of EFL.

Limitations
===========

The present study has some limitations. First, it was a single-center investigation, so some degree of selection bias might have affected the findings. Second, it was based on a small number of patients, and a larger study population would be required to validate the results. Third, although a previous study showed that exacerbations in COPD significantly affected progression of emphysema detected by computed tomography, emphysema was not evaluated in this study. Longitudinal studies in consideration of emphysema will be needed. Fourth, there might be an influence of changes and/or addition of treatment during the observation period on the results in our study.

Conclusion
==========

In conclusion, this study showed an annual increase in respiratory system impedance and those exacerbations could accelerate this increase in patients with COPD. Respiratory system impedance might reflect the clinical course of COPD and the impact of exacerbations on the airways more clearly than pulmonary function tests, and there is the possibility that FOT could be useful for longtime assessment of COPD.
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###### 

Characteristics of subjects at enrollment

                                N=51
  ----------------------------- ----------------------
  Observation period (months)   57 (52--59)
  Age (years)                   72 (64--76)
  Sex (male/female)             43/8
  Body mass index (kg/m^2^)     20.9 (18.8--23.0)
  Smoking state (current/ex)    11/40
  Smoking (pack-year)           45 (30--70)
  GOLD stage (1/2/3/4)          2/30/18/1
  Medication for COPD           
   Any medications              47
   LAMA                         47
   ICS + LABA                   19
  COPD assessment test score    6 (3--10)
  Neutrophils (/µL)             3,602 (3,130--4,295)
  Eosinophils (/µL)             156 (98.3--231)
  IgE (IU/mL)                   78 (18--173)
  FeNO (ppb)                    15 (11--20)

**Notes:** Values are shown as the median (25%--75%). Neutrophils, eosinophils, and IgE were measured in blood.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; IgE, immunoglobulin E; FeNO, fractional exhaled nitric oxide; ppb, parts per billion.

###### 

Respiratory system impedance and FEV~1~ at enrollment

                          N=51
  ----------------------- ------------------------
  R5 (cmH~2~O/L/s)        
   Whole breath           3.52 (2.51--4.02)
   Inspiratory            3.20 (2.29--3.67)
   Expiratory             3.62 (2.68--4.23)
   ⊿R5                    0.42 (0.18--0.8)
  R20 (cmH~2~O/L/s)       
   Whole breath           2.54 (2.14--2.98)
   Inspiratory            2.28 (1.80--2.65)
   Expiratory             2.62 (2.25--3.23)
   ⊿R20                   0.22 (0.11--0.44)
  R5--R20 (cmH~2~O/L/s)   
   Whole breath           1.14 (0.51--1.51)
   Inspiratory            0.98 (0.27--1.56)
   Expiratory             0.91 (0.22--1.49)
   ⊿R5--R20               0.30 (0.10--0.65)
  X5 (cmH~2~O/L/s)        
   Whole breath           −1.14 (−2.02 to −0.70)
   Inspiratory            −0.82 (−1.60 to −0.56)
   Expiratory             −1.27 (−2.10 to −0.59)
   ⊿X5                    −0.36 (−1.00 to −0.11)
  Fres (Hz)               
   Whole breath           12.35 (8.51--15.13)
   Inspiratory            11.13 (8.14--14.52)
   Expiratory             12.99 (8.95--16.62)
   ⊿Fres                  1.00 (−0.05--2.79)
   FEV~1~ (L)             1.38 (0.95--1.80)

**Notes:** Values are shown as the median (25%--75%). ⊿, difference between inspiratory and expiratory phases.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; R5, respiratory system resistance at 5 Hz; R20, respiratory system resistance at 20 Hz; X5, respiratory system reactance at 5 Hz; Fres, resonant frequency.

###### 

Annual changes of respiratory system impedance and FEV~1~

                          Annual change
  ----------------------- ---------------------------
  R5 (cmH~2~O/L/s)        
   Whole breath           0.055 (−0.144--0.227)
   Inspiratory            0.039 (−0.101--0.190)
   Expiratory             0.024 (−0.169--0.251)
   ⊿R5                    0.007 (−0.078--0.056)
  R20 (cmH~2~O/L/s)       
   Whole breath           0.058 (−0.030--0.143)
   Inspiratory            −0.006 (−0.179--0.139)
   Expiratory             0.039 (−0.213--0.196)
   ⊿R20                   −0.005 (−0.049--0.053)
  R5--R20 (cmH~2~O/L/s)   
   Whole breath           0.013 (−0.162--0.191)
   Inspiratory            −0.036 (−0.172--0.216)
   Expiratory             0.014 (−0.171--0.138)
   ⊿R5--R20               0.024 (−0.068--0.075)
  X5 (cmH~2~O/L/s)        
   Whole breath           −0.087 (−0.231 to −0.005)
   Inspiratory            −0.075 (−0.172 to −0.017)
   Expiratory             −0.110 (−0.309--0.011)
   ⊿X5                    −0.050 (−0.156--0.068)
  Fres (Hz)               
   Whole breath           0.733 (0.340--1.140)
   Inspiratory            0.510 (0.317--1.045)
   Expiratory             0.747 (0.222--1.259)
   ⊿Fres                  0.105 (−0.233--0.558)
   FEV~1~(mL)             −24.6 (−55.2--4.4)

**Notes:** Values are shown as the median (25%--75%). ⊿, difference between inspiratory and expiratory phases.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; R5, respiratory system resistance at 5 Hz; R20, respiratory system resistance at 20 Hz; X5, respiratory system reactance at 5 Hz; Fres, resonant frequency.

###### 

Characteristics of subjects with and without exacerbations at enrollment

                                           Exacerbation                                           Nonexacerbation        *P*-value
  ---------------------------------------- ------------------------------------------------------ ---------------------- -----------
  Subjects (n)                             25                                                     26                     
  Sex (male/female)                        24/1                                                   19/7                   
  Age (years)                              72.0 (66.5--74.5)                                      71.5 (61.8--78.5)      0.92
  Smoking history (pack-year)              45 (25--65)                                            47.5 (30--65)          0.29
  Smoking of recruitment                   15 (60%)                                               12 (46%)               
  BMI (kg/m^2^)                            23.5 (20.4--25.8)                                      21.8 (20.4--23.8)      0.18
  COPD assessment test score               6 (3--10)                                              6 (4--10)              0.69
  GOLD stage (1/2/3/4)                     1/14/10/0                                              1/16/8/1               
  Exacerbation in last year                [\*](#tfn8-copd-12-509){ref-type="table-fn"}1 (1--1)   0 (0--1)               \<0.01
  Exacerbation during observation period   0.44 (0.23--0.63)                                      0 (0--0)               
  Neutrophils (/µL)                        3,495 (2,960--3,907)                                   3,708 (3,264--4,873)   0.06
  Eosinophils (/µL)                        148 (58--223)                                          176 (50--218)          0.75
  IgE (IU/mL)                              54 (13--108)                                           95 (23--123)           0.52
  FeNO (ppb)                               15 (11--19)                                            15 (12--23)            0.47

**Notes:** Values are shown as the median (25%--75%).

*P*\<0.05. Neutrophils, eosinophils, and IgE were measured in blood.

**Abbreviations:** BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IgE, immunoglobulin E; FeNO, fractional exhaled nitric oxide; ppb, parts per billion.

###### 

Respiratory system impedance and FEV~1~ of subjects with and without exacerbations at enrollment

                          Exacerbation             Nonexacerbation          *P*-value
  ----------------------- ------------------------ ------------------------ -----------
  Subjects (n)            25                       26                       
  R5 (cmH~2~O/L/s)                                                          
   Whole breath           3.29 (2.09--3.78)        3.66 (3.11--4.20)        0.06
   Inspiratory            3.02 (1.95--3.57)        3.35 (2.88--4.12)        0.06
   Expiratory             3.56 (2.13--4.26)        3.74 (3.29--4.33)        0.21
   ⊿R5                    0.40 (0.20--0.80)        0.44 (0.17--1.00)        0.95
  R20 (cmH~2~O/L/s)                                                         
   Whole breath           2.54 (2.15--2.99)        2.54 (2.09--2.98)        0.44
   Inspiratory            2.44 (2.09--2.79)        2.10 (1.71--2.54)        0.16
   Expiratory             2.64 (2.28--3.30)        2.60 (2.25--3.22)        0.87
   ⊿R20                   0.18 (0.06--0.34)        0.23 (0.11--0.44)        0.28
  R5--R20 (cmH~2~O/L/s)                                                     
   Whole breath           0.93 (0.43--1.58)        1.15 (0.68--1.47)        0.37
   Inspiratory            0.78 (0.21--1.76)        1.29 (0.48--1.56)        0.06
   Expiratory             0.86 (0.17--1.51)        1.06 (0.42--1.31)        0.74
   ⊿R5--R20               0.37 (0.16--0.96)        0.20 (0.04--0.51)        0.25
  X5 (cmH~2~O/L/s)                                                          
   Whole breath           −0.96 (−1.62 to −0.57)   −1.20 (−2.58 to −0.80)   0.08
   Inspiratory            −0.69 (−1.33 to −0.43)   −0.80 (−1.76 to −0.65)   0.14
   Expiratory             −0.97 (−2.05 to −0.50)   −1.35 (−2.38 to −0.79)   0.09
   ⊿X5                    −0.24 (−0.62 to −0.08)   −0.52 (−1.68--0.10)      0.30
  Fres (Hz)                                                                 
   Whole breath           12.02 (8.86--14.75)      12.51 (10.45--16.30)     0.22
   Inspiratory            11.04 (8.59--14.06)      11.70 (8.82--13.89)      0.74
   Expiratory             12.51 (8.87--16.41)      13.36 (10.74--16.61)     0.29
   ⊿Fres                  1.03 (0.21--2.43)        0.99 (−0.46--3.70)       0.81
  FEV~1~(L)               1.40 (0.98--1.84)        1.31 (0.95--1.70)        0.60

**Note:** Values are shown as the median (25%--75%). ⊿, difference between inspiratory and expiratory phases.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; R5, respiratory system resistance at 5 Hz; R20, respiratory system resistance at 20 Hz; X5, respiratory system reactance at 5 Hz; Fres, resonant frequency.

###### 

Annual changes of respiratory system impedance and FEV~1~ of subjects with and without exacerbations at enrollment

                          Exacerbation                                                             Nonexacerbation             *P*-value
  ----------------------- ------------------------------------------------------------------------ --------------------------- -----------
  Subjects (n)            25                                                                       26                          
  R5 (cmH~2~O/L/s)                                                                                                             
   Whole breath           [\*](#tfn13-copd-12-509){ref-type="table-fn"}0.188 (0.056--0.310)        −0.037 (−0.170--0.103)      \<0.01
   Inspiratory            [\*](#tfn13-copd-12-509){ref-type="table-fn"}0.146 (0.052--0.268)        −0.039 (−0.145--0.081)      \<0.01
   Expiratory             [\*](#tfn13-copd-12-509){ref-type="table-fn"}0.187 (0.019--0.360)        −0.021 (−0.128--0.124)      \<0.01
   ⊿R5                    0.010 (−0.048--0.095)                                                    −0.003 (−0.085--0.053)      0.40
  R20 (cmH~2~O/L/s)                                                                                                            
   Whole breath           0.048 (−0.041--0.159)                                                    −0.065 (−0.025--0.124)      0.52
   Inspiratory            0.047 (−0.114--0.163)                                                    −0.105 (−0.216--0.151)      0.20
   Expiratory             0.044 (−0.117--0.155)                                                    −0.073 (−0.278--0.215)      0.34
   ⊿R20                   0.001 (−0.065--0.067)                                                    −0.018 (−0.049--0.038)      0.45
  R5--R20 (cmH~2~O/L/s)                                                                                                        
   Whole breath           0.041 (−0.076--0.232)                                                    −0.093 (−0.229--0.114)      0.07
   Inspiratory            [\*](#tfn13-copd-12-509){ref-type="table-fn"}0.050 (−0.101--0.294)       −0.152 (−0.183--0.142)      0.02
   Expiratory             0.060 (−0.146--0.234)                                                    −0.053 (−0.211--0.096)      0.10
   ⊿R5--R20               −0.006 (−0.134--0.076)                                                   0.028 (−0.055--0.070)       0.56
  X5 (cmH~2~O/L/s)                                                                                                             
   Whole breath           [\*](#tfn13-copd-12-509){ref-type="table-fn"}−0.183 (−0.258 to −0.099)   −0.017 (−0.092--0.016)      \<0.01
   Inspiratory            [\*](#tfn13-copd-12-509){ref-type="table-fn"}−0.103 (−0.212 to −0.056)   −0.049 (−0.127 to −0.023)   0.03
   Expiratory             [\*](#tfn13-copd-12-509){ref-type="table-fn"}−0.257 (−0.309 to −0.067)   0.006 (−0.140--0.092)       \<0.01
   ⊿X5                    [\*](#tfn13-copd-12-509){ref-type="table-fn"}−0.121 (−0.228 to −0.012)   −0.004 (−0.073--0.148)      \<0.01
  Fres (Hz)                                                                                                                    
   Whole breath           [\*](#tfn13-copd-12-509){ref-type="table-fn"}1.044 (0.669--1.434)        0.266 (−0.022--0.767)       \<0.01
   Inspiratory            [\*](#tfn13-copd-12-509){ref-type="table-fn"}0.891 (0.392--1.185)        0.410 (0.142--0.556)        \<0.01
   Expiratory             [\*](#tfn13-copd-12-509){ref-type="table-fn"}1.013 (0.632--1.384)        0.293 (−0.029--0.839)       \<0.01
   ⊿Fres                  0.239 (−0.289--0.662)                                                    0.014 (−0.198--0.553)       0.26
  FEV~1~ (mL)             [\*](#tfn13-copd-12-509){ref-type="table-fn"}−38.6 (−79.3--5.8)          −14.2 (−31.7--12.2)         \<0.01

**Notes:** Values are shown as the median (25%--75%).

*P*\<0.05. ⊿, difference between inspiratory and expiratory phases.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; R5, respiratory system resistance at 5 Hz; R20, respiratory system resistance at 20 Hz; X5, respiratory system reactance at 5 Hz; Fres, resonant frequency.
